{"count":238,"next":null,"previous":"https://memento.epfl.ch/api/v1/events/?format=json&limit=10&offset=220&ordering=event__academic_calendar_category","results":[{"id":72066,"title":"Electrochemical deposition of composite materials: unravelling the process-structure-property nexus","slug":"electrochemical-deposition-of-composite-material-2","event_url":"https://memento.epfl.ch/event/electrochemical-deposition-of-composite-material-2","visual_url":"https://memento.epfl.ch/image/33358/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33358/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33358/max-size.jpg","lang":"en","start_date":"2026-06-19","end_date":"2026-06-19","start_time":"17:00:00","end_time":null,"description":"<p>Thesis Directors: Dr. S. Mischler, Prof. R. Logé<br>\r\nMaterials Science and Engineering doctoral program<br>\r\nThesis Nr. 11821<br>\r\n<br>\r\nTo take part in the public defense, please contact directly the speaker</p>","image_description":"","creation_date":"2026-06-08T16:04:36","last_modification_date":"2026-06-08T16:04:39","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"MXF 1","url_place_and_room":"https://plan.epfl.ch/?room==MXF%201","url_online_room":"https://epfl.zoom.us/j/7308250564","spoken_languages":[],"speaker":"<a href=\"mailto:ayush.khurana@epfl.ch\"><strong>Ayush KHURANA</strong></a>","organizer":"","contact":"<a href=\"mailto:ayush.khurana@epfl.ch\"><strong>Ayush KHURANA</strong></a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"EDMX","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121026/","category":{"id":12,"code":"SOUTE","fr_label":"Soutenances de thèses","en_label":"Thesis defenses","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/1/?format=json","https://memento.epfl.ch/api/v1/mementos/6/?format=json"]},{"id":72068,"title":"Development of TOPCon-based Solar Cell Architectures : From Single-Junction Silicon Cells to Perovskite-Silicon Tandems","slug":"development-of-topcon-based-solar-cell-architect-2","event_url":"https://memento.epfl.ch/event/development-of-topcon-based-solar-cell-architect-2","visual_url":"https://memento.epfl.ch/image/33359/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33359/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33359/max-size.jpg","lang":"en","start_date":"2026-07-09","end_date":"2026-07-09","start_time":"17:00:00","end_time":null,"description":"<p>Thesis Directors: Dr. F.-J. Haug, Prof. C. Ballif<br>\r\nPhotonics doctoral program<br>\r\nThesis Nr. 11549<br>\r\n<br>\r\nTo take part in the public defense, please contact directly the speaker</p>","image_description":"","creation_date":"2026-06-08T16:13:04","last_modification_date":"2026-06-08T16:13:08","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"MC A1 272","url_place_and_room":"https://plan.epfl.ch/?room==MC%20A1%20272","url_online_room":"https://epfl.zoom.us/j/68263660992","spoken_languages":[],"speaker":"<a href=\"mailto:julien.hurni@epfl.ch\"><strong>Julien HURNI</strong></a>","organizer":"","contact":"<a href=\"mailto:julien.hurni@epfl.ch\"><strong>Julien HURNI</strong></a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"EDPO, MicrocityPhD","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121029/","category":{"id":12,"code":"SOUTE","fr_label":"Soutenances de thèses","en_label":"Thesis defenses","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/1/?format=json","https://memento.epfl.ch/api/v1/mementos/6/?format=json"]},{"id":72069,"title":"U.S. CDMRP – Peer Reviewed Medical Research Program| Research Funding","slug":"us-cdmrp-peer-reviewed-medical-research-program--3","event_url":"https://memento.epfl.ch/event/us-cdmrp-peer-reviewed-medical-research-program--3","visual_url":"https://memento.epfl.ch/image/33361/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33361/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33361/max-size.jpg","lang":"en","start_date":"2026-07-16","end_date":"2026-07-16","start_time":null,"end_time":null,"description":"<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Peer Reviewed Medical Research Program (PRMRP). </strong>Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Clinical Trial Award s</strong>upports the rapid execution and analysis of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the Topic Areas and one of the Strategic Goals. Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.</li>\r\n\t<li>The <strong>Discovery Award</strong> supports innovative, untested, non-incremental, high risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications with impact on one of the Topic Areas and one of the Strategic Goals.</li>\r\n\t<li>The <strong>Impact Award </strong>supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research and insights from the real-world environment to foster clinical applicability. Applications should demonstrate the potential to make a near-term, major impact on one of the Topic Areas and one of the Strategic Goals.</li>\r\n\t<li>The <strong>Lifestyle and Applied Health Research Award</strong> supports clinical research and/or clinical trials using a combination of scientific disciplines, including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health.  Applications must address and provide a solution to one of the Topic Areas and one of the Strategic Goals.</li>\r\n\t<li>The <strong>Platform Clinical Translation Award</strong> supports the translational development and/or early phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two Topic Areas. Applications must address one of the Strategic Goals.</li>\r\n\t<li>The <strong>Research Advancement Award</strong> supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the Topic Areas and one of the Strategic Goals.</li>\r\n\t<li>The <strong>Technology/Therapeutic Development Award</strong> supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the Topic Areas and one of the Strategic Goals. Applications must describe product-oriented research. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines.</li>\r\n</ul>\r\n<sup>Please see Section 3.2.1 <strong>'FY26 PRMRP Topic Areas and Strategic Goals'</strong> under the respective Award/Funding Opportunity Number.</sup><br>\r\n<br>\r\n<strong>Funding</strong>:      <br>\r\nClinical Trial Award: $6M-$20M<br>\r\nDiscovery Award: max. $385K<br>\r\nImpact Award: $2.8M-$3.6M<br>\r\nLifestyle and Applied Health Research Award: max. $4.2M<br>\r\nPlatform Clinical Translation Award: max. $15M<br>\r\nResearch Advancement Award: max. $1.4M<br>\r\nTechnology/Therapeutic Development Award: max. $5.6M<br>\r\n<br>\r\n<sup>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sup><br>\r\n<br>\r\n<br>\r\n<strong>Duration</strong>:     <br>\r\nClinical Trial Award: 4 years<br>\r\nDiscovery Award: 2 years<br>\r\nImpact Award: 4 years<br>\r\nLifestyle and Applied Health Research Award: 4 years<br>\r\nPlatform Clinical Translation Award: 4 years<br>\r\nResearch Advancement Award: 4 years<br>\r\nTechnology/Therapeutic Development Award: 4 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline:            </strong>\r\n\r\n<ul>\r\n\t<li><strong>16 July 2026, </strong>5:00 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Discovery Award</li>\r\n\t\t<li>Research Advancement Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>23 July 2026, </strong>5:00 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Clinical Trial Award</li>\r\n\t\t<li>Impact Award</li>\r\n\t\t<li>Lifestyle and Applied Health Research Award</li>\r\n\t\t<li>Platform Clinical Translation Award</li>\r\n\t\t<li>Technology/Therapeutic Development Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>Full Application Deadline</strong>:          \r\n\r\n<ul>\r\n\t<li><strong>30 July 2026, </strong>11:59 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Discovery Award</li>\r\n\t\t<li>Research Advancement Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>06 August 2026, </strong>11:59 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Impact Award</li>\r\n\t\t<li>Lifestyle and Applied Health Research Award</li>\r\n\t\t<li>Technology/Therapeutic Development Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>22 September 2026, </strong>11:59 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Clinical Trial Award</li>\r\n\t\t<li>Platform Clinical Translation Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n                                             <br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719111\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255299&amp;fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:research@epfl.ch\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36283308&amp;fileType=pdf\">HT942526PRMRPCTA</a></li>\r\n\t\t<li>Discovery Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255277&amp;fileType=pdf\">HT942526PRMRPDA</a></li>\r\n\t\t<li>Impact Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255284&amp;fileType=pdf\">HT942526PRMRPIPA</a></li>\r\n\t\t<li>Lifestyle and Applied Health Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255290&amp;fileType=pdf\">HT942526PRMRPLAHRA</a></li>\r\n\t\t<li>Platform Clinical Translation Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36283302&amp;fileType=pdf\">HT942526PRMRPPCTA</a></li>\r\n\t\t<li>Research Advancement Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255279&amp;fileType=pdf\">HT942526PRMRPRAA</a></li>\r\n\t\t<li>Technology/Therapeutic Development Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36255283&amp;fileType=pdf\">HT942526PRMRPTTDA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>","image_description":"","creation_date":"2026-06-08T16:59:21","last_modification_date":"2026-06-08T17:01:35","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"","url_place_and_room":"","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"","organizer":"","contact":"<a href=\"mailto:research@epfl.ch\">Research Office</a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121030/","category":{"id":16,"code":"PROP","fr_label":"Appel à proposition","en_label":"Call for proposal","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/9/?format=json","https://memento.epfl.ch/api/v1/mementos/140/?format=json"]},{"id":72070,"title":"U.S. CDMRP – Traumatic Brain Injury and Psychological Health Research Program | Research Funding","slug":"us-cdmrp-traumatic-brain-injury-and-psychological","event_url":"https://memento.epfl.ch/event/us-cdmrp-traumatic-brain-injury-and-psychological","visual_url":"https://memento.epfl.ch/image/33362/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33362/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33362/max-size.jpg","lang":"en","start_date":"2026-07-13","end_date":"2026-07-13","start_time":null,"end_time":null,"description":"<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Traumatic Brain Injury and Psychological Health Research Program (TBIPH). </strong>Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Clinical Trial Award </strong>supports the rapid execution of clinical trials with the potential to have a significant impact on the treatment or management of psychological health conditions and/or traumatic brain injuries. Proposed research may range from proof-of-concept trials that establish feasibility to larger scale and advanced trials that evaluate effectiveness.</li>\r\n\t<li>The <strong>Health Services Research Award </strong>supports high-impact research that bridges the gap between research, practice, and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can by deployed to targeted populations at the appropriate time.</li>\r\n\t<li>The <strong>Translational Research Award </strong>supports research that accelerates the conversion of scientific findings in psychological health and/or TBI into impactful clinical applications. Prioritizes innovative approaches over purely iterative or incremental research. Research outcomes must clearly lead to the development of transformative health care products, technologies, or clinical practice guidelines. Additional information about translational research can be found here: <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829707/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829707/</a> and <a href=\"https://ncats.nih.gov/about/about-translational-science\">https://ncats.nih.gov/about/about-translational-science</a>.</li>\r\n</ul>\r\n<sub>All applications must specifically address at least one of the topics<strong> </strong>listed in <strong>Section 3.2.1 'Focus Areas'</strong> under the respective Award/Funding Opportunity Number.</sub><br>\r\n<br>\r\n<strong>Funding</strong>:      <br>\r\nClinical Trial Award: $2.1M - $4.1M<br>\r\nHealth Services Research Award: max. $4.0M  <br>\r\nTranslational Research Award: $1,0M-$2,0M<br>\r\n<br>\r\n<sup><sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub></sup><br>\r\n<br>\r\n<strong>Duration</strong>:     <br>\r\nClinical Trial Award: 4 years<br>\r\nHealth Services Research Award: 4years<br>\r\nTranslational Research Award: 4 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline:          <br>\r\n13 July 2026, </strong>5:00 p.m. Eastern time for the Clinical Trial Award &amp; Translational Research Award<br>\r\n<strong>24 September 2026, </strong>5:00 p.m. Eastern time for the Health Services Research Award<br>\r\n                         <br>\r\n<strong>Full Application Deadline</strong>:         <br>\r\n<strong>15 October 2026</strong>, 11:59 p.m. Eastern Time for all awards<br>\r\n                                                           <br>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=723102\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36261231&amp;fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:research@epfl.ch\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers: \r\n\t<ul>\r\n\t\t<li>Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36261241&amp;fileType=pdf\">HT942526TBIPHRPCTA</a></li>\r\n\t\t<li>Health Services Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36261230&amp;fileType=pdf\">HT942526TBIPHRPHSRA</a></li>\r\n\t\t<li>Translational Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36261250&amp;fileType=pdf\">HT942526TBIPHRPTRA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>","image_description":"","creation_date":"2026-06-08T18:14:54","last_modification_date":"2026-06-08T18:14:54","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"","url_place_and_room":"","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"","organizer":"","contact":"<a href=\"mailto:research@epfl.ch\">Research Office</a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121031/","category":{"id":16,"code":"PROP","fr_label":"Appel à proposition","en_label":"Call for proposal","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/9/?format=json","https://memento.epfl.ch/api/v1/mementos/140/?format=json"]},{"id":72071,"title":"U.S. CDMRP – Melanoma Research Program | Research Funding","slug":"us-cdmrp-melanoma-research-program-research-fundin","event_url":"https://memento.epfl.ch/event/us-cdmrp-melanoma-research-program-research-fundin","visual_url":"https://memento.epfl.ch/image/33363/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33363/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33363/max-size.jpg","lang":"en","start_date":"2026-07-13","end_date":"2026-07-13","start_time":null,"end_time":null,"description":"<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Melanoma Research Program (MRP)</strong>. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Focused Program Award - Rare Melanomas </strong>supports a multidisciplinary rare melanoma research program of at least two, but not more than three, distinct but complementary projects. The completion of one project must not depend on the completion of another project. Applications must propose a unifying, overarching question that addresses a critical unmet need relevant to rare melanoma research and/or patient care.</li>\r\n\t<li>The <strong>Idea Award </strong>supports untested, exploratory, high risk/potentially high-reward concepts, theories, paradigms or methods. The intent is to generate new research avenues for investigation. Novelty and innovation should be key aspects of the proposed project. All applications must specifically address at least one of the <strong>Focus Areas </strong>listed in <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243289&amp;fileType=pdf\">this document</a>.</li>\r\n\t<li>The <strong>Survivorship Research Award </strong>supports studies addressing melanoma specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners.</li>\r\n\t<li><strong>Team Science Award</strong> Supports new or existing partnerships between two or three PIs to address a single research problem or question in a manner that would be unachievable through separate efforts. All applications must specifically address at least one of the <strong>Focus Areas </strong>listed in <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243291&amp;fileType=pdf\">this document</a>.</li>\r\n</ul>\r\n<br>\r\n<strong>Funding</strong>:      <br>\r\n<strong>Focused Program Award - Rare Melanomas</strong>: max. $2.8M<br>\r\n<strong>Idea Award</strong>: max. $560K<br>\r\n<strong>Survivorship Research Award</strong>: max. $1,02M<br>\r\n<strong>Team Science Award: </strong>max.<strong> </strong>$2.1M<br>\r\n<sup><sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub></sup><br>\r\n<br>\r\n<strong>Duration</strong>:     <br>\r\n<strong>Focused Program Award - Rare Melanomas</strong>: 4 years<br>\r\n<strong>Idea Award</strong>: 2 years<br>\r\n<strong>Survivorship Research Award</strong>: 3 years<br>\r\n<strong>Team Science Award: </strong>3 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline:            </strong>\r\n\r\n<ul>\r\n\t<li><strong>13 July 2026, </strong>5:00 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Focused Program Award - Rare Melanomas</li>\r\n\t\t<li>Idea Award</li>\r\n\t\t<li>Team Science Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>22 September 2026, </strong>5:00 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Survivorship Research Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>Full Application Deadline</strong>:          \r\n\r\n<ul>\r\n\t<li><strong>14 October 2026, </strong>11:59 p.m. Eastern time for all awards</li>\r\n</ul>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=723102\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36261231&amp;fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:research@epfl.ch\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Focused Program Award - Rare Melanomas: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243293&amp;fileType=pdf\">HT942526MRPFPARM</a></li>\r\n\t\t<li>Idea Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243289&amp;fileType=pdf\">HT942526MRPIA</a></li>\r\n\t\t<li>Survivorship Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243295&amp;fileType=pdf\">HT942526MRPSRA</a></li>\r\n\t\t<li>Team Science Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243291&amp;fileType=pdf\">HT942526MRPTSA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>","image_description":"","creation_date":"2026-06-08T19:07:25","last_modification_date":"2026-06-08T19:08:20","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"","url_place_and_room":"","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"","organizer":"","contact":"<a href=\"mailto:research@epfl.ch\">Research Office</a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121032/","category":{"id":16,"code":"PROP","fr_label":"Appel à proposition","en_label":"Call for proposal","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/9/?format=json","https://memento.epfl.ch/api/v1/mementos/140/?format=json"]},{"id":72072,"title":"U.S. CDMRP – Spinal Cord Injury Research Program | Research Funding","slug":"us-cdmrp-spinal-cord-injury-research-program-res-3","event_url":"https://memento.epfl.ch/event/us-cdmrp-spinal-cord-injury-research-program-res-3","visual_url":"https://memento.epfl.ch/image/33364/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33364/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33364/max-size.jpg","lang":"en","start_date":"2026-08-03","end_date":"2026-08-03","start_time":null,"end_time":null,"description":"<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Spinal Cord Injury Research Program (SCIRP) </strong>Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Clinical Trial Award </strong>supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI). Proposed projects may range from small proof of-concept trials (i.e., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large scale trials to determine efficacy in relevant patient populations.</li>\r\n\t<li>The <strong>Clinical Translation Research Award </strong>supports high-impact, new or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation.</li>\r\n\t<li>The <strong>Translational Research Award </strong>supports translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Applications may include preclinical evaluations of interventions and/or clinical studies involving human subjects and human anatomical substances.</li>\r\n\t<li>The <strong>Investigator-Initiated Research Award </strong>supports studies that have the potential to make an important contribution to SCI research, patient care and/or quality of life. Permitted research includes preclinical studies in animal models, research with human subjects or human anatomical substances, as well as ancillary studies associated with an existing clinical trial.</li>\r\n</ul>\r\n<sup>All applications must address at least one of the program Priority Areas and undertake an associated near-term Programmatic Goal. The FY26 SCIRP Priority Areas with Programmatic Goals are listed at the end of this announcement.</sup><br>\r\n<br>\r\n<strong>Funding</strong>:      <br>\r\nClinical Trial Award: $4.8M – $4.96M<br>\r\nClinical Translation Research Award: $2.00M - $2.16M<br>\r\nTranslational Research Award: $2.00M - $2.16M<br>\r\nInvestigator-Initiated Research Award: $800K-$900K<br>\r\n<sup><sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub></sup><br>\r\n<br>\r\n<strong>Duration</strong>:<br>\r\nClinical Trial Award: 4 years<br>\r\nClinical Translation Research Award: 3 years<br>\r\nTranslational Research Award: 3 years<br>\r\nInvestigator-Initiated Research Award: 3 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline:           <br>\r\n03 August 2026, </strong>5:00 p.m. Eastern time<br>\r\n<br>\r\n<strong>Full Application Deadline</strong>:          <br>\r\n<strong>12 November 2026</strong>, 11:59 p.m Eastern Time<br>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719104\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243239&amp;fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:research@epfl.ch\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36225242&amp;fileType=pdf\">HT942526SCIRPCTA</a></li>\r\n\t\t<li>Clinical Translation Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36225238&amp;fileType=pdf\">HT942526SCIRPCTRA</a></li>\r\n\t\t<li>Translational Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36225219&amp;fileType=pdf\">HT942526SCIRPTRA</a></li>\r\n\t\t<li>Investigator-Initiated Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36223295&amp;fileType=pdf\">HT942526SCIRPIIRA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>FY26 SCIRP </strong><strong>Priority Areas With Programmatic Goals:</strong><br>\r\n<br>\r\n<strong>Priority Area: Acute Injury Intervention </strong>\r\n\r\n<ul>\r\n\t<li><strong>Near-Term Goal: </strong>Develop and/or test interventions, e.g., surgical, device, pharmacologic, that protect spinal cord tissue from further damage shortly after injury and can be administered on a timeline suitable for acute trauma care in both battlefield and civilian settings.</li>\r\n\t<li><strong>Long-Term Goal: </strong>Adoption of management/stabilization practices into the standard of care for acute spinal cord injury, leading to meaningfully improved outcomes within the prehospital, hospital, or deployed environments.</li>\r\n</ul>\r\n<br>\r\n<strong>Priority Area: Secondary Health Effects </strong>\r\n\r\n<ul>\r\n\t<li><strong>Near-Term Goal: </strong>Develop and/or test interventions to prevent or manage the secondary health effects of spinal cord injury that impact injury survivors throughout their lifespan.</li>\r\n\t<li><strong>Long-Term Goal: </strong>Adoption of interventions into the standard of care that significantly reduce the burden of secondary health effects and improve the lifelong health of SCI survivors.</li>\r\n</ul>\r\n<strong>Priority Area: Psychosocial Well-Being </strong>\r\n\r\n<ul>\r\n\t<li><strong>Near-Term Goal: </strong>Develop and/or test psychosocial interventions that are specifically tailored to the unique needs of individuals with SCI, their families, and/or care partners.</li>\r\n\t<li><strong>Long-Term Goal: </strong>Adoption of interventions into the standard of care that promote psychosocial well-being for people with SCI, their families, and/or care partners.</li>\r\n</ul>\r\n<strong>Priority Area: Rehabilitation and Regeneration </strong>\r\n\r\n<ul>\r\n\t<li><strong>Near-Term Goal: </strong>Develop and/or test rehabilitation, regenerative, or neuroplastic interventions for individuals with spinal cord injury that can be implemented at any stage of life post-injury.</li>\r\n\t<li><strong>Long-Term Goal: </strong>Adoption of validated rehabilitation and regenerative therapies into the standard of care that meaningfully improve function, independence, and quality of life after SCI.</li>\r\n</ul>","image_description":"","creation_date":"2026-06-08T20:12:30","last_modification_date":"2026-06-08T20:13:47","link_label":"","link_url":"","canceled":"False","cancel_reason":"","place_and_room":"","url_place_and_room":"","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"","organizer":"","contact":"<a href=\"mailto:research@epfl.ch\">Research Office</a>","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121033/","category":{"id":16,"code":"PROP","fr_label":"Appel à proposition","en_label":"Call for proposal","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/9/?format=json","https://memento.epfl.ch/api/v1/mementos/140/?format=json"]},{"id":72073,"title":"Showcase, E4S Impact Innovation Summit","slug":"showcase-e4s-impact-innovation-summit","event_url":"https://memento.epfl.ch/event/showcase-e4s-impact-innovation-summit","visual_url":"https://memento.epfl.ch/image/33365/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33365/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33365/max-size.jpg","lang":"en","start_date":"2026-09-17","end_date":"2026-09-17","start_time":"09:00:00","end_time":"19:00:00","description":"<p>Showcase is Lausanne’s impact innovation summit bringing together actors from academia, business and the public sector to rethink and shape the economy of tomorrow. <br>\r\n<br>\r\n<strong>Program:</strong><br>\r\n<em>During the whole day, the public can visit an exhibition of 18+ solutions to restore, monitor and protect nature</em><br>\r\n<br>\r\n08:30 Coffee &amp; Croissants<br>\r\n09:00 Welcome and Keynote by Julia Binder (Professor of Business Transformation, IMD)<br>\r\n09:30 Thematic Workshops and Impact Innovation Award by FIT (Fondation pour l'Innovation et la Technologie)<br>\r\n<br>\r\n12:00 Lunch Break<br>\r\n<br>\r\n13:15 Keynote speeches, fireside chats and debates starring Cyril Dion (Author and Movie Director), Christophe Champod (Rector, UNIL), and many more<br>\r\n<br>\r\n15:00 Break<br>\r\n<br>\r\n15:30 Keynote speeches, fireside chats and debates starring Emmanuel Faber (Chair, International Sustainability Standards and former CEO of Danone), Camille Etienne (author, activist and director of the NGO <em>Avant l'Orage</em>), and many more<br>\r\n<br>\r\n17:00 Closing ceremony<br>\r\n<br>\r\n17:30 Cocktail reception <br>\r\n<br>\r\n<br>\r\n </p>","image_description":"Showcase Event Flyer | 17 September 2026, STCC Lausanne","creation_date":"2026-06-08T21:21:32","last_modification_date":"2026-06-09T09:44:56","link_label":"Register here","link_url":"https://e4s.center/showcase/","canceled":"False","cancel_reason":"","place_and_room":"STCC -1 9100","url_place_and_room":"https://plan.epfl.ch/?room==STCC%20-1%209100","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/1/?format=json","https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"Emmanuel Faber (Chair, International Sustainability Standards ISSB and former CEO of Danone)<br>\r\nCamille Etienne (author, activist, and director of the NGO <em>Avant l'Orage</em>)<br>\r\nCyril Dion (author and filmmaker)<br>\r\nChristophe Champod (Rector, UNIL)<br>\r\nJulia Binder (Professor of Business Transformation, IMD)","organizer":"Enterprise for Society Center (E4S)","contact":"Federica Poletti, Head of Communications, E4S: federica.poletti@epfl.ch  Justine Le Cam, Communication and Events Manager, E4S: justine.lecam@epfl.ch","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":1,"fr_label":"Sur inscription","en_label":"Registration required"},"keywords":"impact, innovation, sustainability","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121034/","category":{"id":1,"code":"CONF","fr_label":"Conférences - Séminaires","en_label":"Conferences - Seminars","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/1/?format=json","https://memento.epfl.ch/api/v1/mementos/3/?format=json","https://memento.epfl.ch/api/v1/mementos/6/?format=json","https://memento.epfl.ch/api/v1/mementos/79/?format=json","https://memento.epfl.ch/api/v1/mementos/145/?format=json"]},{"id":72074,"title":"IMX Talks - Interplay of Cooper Quartets, Finite Momentum Pairing, and Josephson Diode Effect in 1T Transition Metal Dichalcogenides","slug":"imx-talks-interplay-of-cooper-quartets-finite-mo-2","event_url":"https://memento.epfl.ch/event/imx-talks-interplay-of-cooper-quartets-finite-mo-2","visual_url":"https://memento.epfl.ch/image/33366/200x112.jpg","visual_large_url":"https://memento.epfl.ch/image/33366/720x405.jpg","visual_maxsize_url":"https://memento.epfl.ch/image/33366/max-size.jpg","lang":"en","start_date":"2026-06-15","end_date":"2026-06-15","start_time":"11:00:00","end_time":"12:00:00","description":"<p>Supercurrent diode effects have recently attracted much attention for their potential applications in superconducting logic circuits, rectification applications and also in the study of fundamental symmetries of the underlying superconducting order parameter. In this talk, I’ll introduce the idea of finite momentum Cooper pairing (FMCP) in systems with strong helical spin-momentum locking and how this can naturally give rise to non-reciprocity in superconducting critical currents namely the Josephson diode effect (JDE). I’ll describe our work establishing the presence of a large JDE due to FMCP in lateral Josephson junctions formed from centrosymmetric van der Waals type-II Dirac semimetals 1T-NiTe<sub>2</sub> and 1T-PtTe<sub>2</sub>. A theoretical analysis based on a Ginzburg-Landau type model suggests that the FMCP introduces a phase difference between the first (Cooper pair) and second (Cooper quartet) harmonic supercurrents, which manifests as the JDE. Measurements of the JDE as a function of the in-plane magnetic field and half-flux quantum oscillations in the JDE are in good agreement with the predictions, indicating the presence of large second harmonic supercurrents in the junction. Surface modifications are shown to strongly enhance the supercurrents in the junction, nearly by a factor of two, indicating the strong contribution of the topological surface states to the supercurrent transport. Overall, 1T systems provide an interesting platform for exploring the interplay of FMCP, JDE and topological superconductivity.<br>\r\n<br>\r\nBio: Dr. Pranava Keerthi Sivakumar completed his Bachelors and Masters in Chemistry with a minor in Physics from the Indian Institute of Science, Bengaluru, India in 2017. He then moved to Germany where he completed his Ph.D. at the Martin Luther University in Halle, graduating <em>summa cum laude</em>. During his Ph.D., he worked on studying the electrical transport properties of materials with non-collinear spin textures and unconventional superconductivity due to strong spin-orbit coupling. Most notably during his Ph.D., he uncovered the role of finite momentum pairing induced Josephson diode effect in topological materials with helical spin-momentum. He is currently a postdoctoral researcher at the NISE department in the Max Planck Institute of Microstructure Physics, focusing on the interplay of magnetization dynamics and supercurrent transport in superconductor-ferromagnet heterostructures.</p>","image_description":"","creation_date":"2026-06-09T08:05:28","last_modification_date":"2026-06-09T08:05:47","link_label":"Website","link_url":"https://www.mpi-halle.mpg.de/NISE/members/152895","canceled":"False","cancel_reason":"","place_and_room":"BM 3241","url_place_and_room":"https://plan.epfl.ch/?room==BM%203241","url_online_room":"","spoken_languages":["https://memento.epfl.ch/api/v1/spoken_languages/2/?format=json"],"speaker":"Dr. Pranava Keerthi Sivakumar, Department of Nano-systems from Ions, Spins and Electrons(NISE), Max Planck Institute of Microstructure Physics, Halle, Germany","organizer":"Prof. Dirk Grundler","contact":"Prof. Dirk Grundler","is_internal":"False","theme":"","vulgarization":{"id":1,"fr_label":"Tout public","en_label":"General public"},"registration":{"id":3,"fr_label":"Entrée libre","en_label":"Free"},"keywords":"","file":null,"icalendar_url":"https://memento.epfl.ch/event/export/121036/","category":{"id":1,"code":"CONF","fr_label":"Conférences - Séminaires","en_label":"Conferences - Seminars","activated":true},"academic_calendar_category":null,"domains":[],"mementos":["https://memento.epfl.ch/api/v1/mementos/314/?format=json"]}]}